21 completed, 2 active not recruiting, 2 recruiting, 1 not yet recruiting. 19 Phase 1, 7 Phase 2, 6 Phase 3.
Follow CStone Pharmaceuticals: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Sugemalimab (or Placebo) Plus PGemOx Regimen in Participants With Extranodal NK/T-Cell Lymphoma Sugemalimab, Placebo, Pegaspargase - Extranodal NK/T-cell Lymphoma | Phase 3 | Not yet recruiting | CStone Pharmaceuticals | 150 | 2027-06-01 | 2026-05-27 |
| A Phase I Study of CS5007 in Participants With Advanced Solid Tumors CS5007 - Advanced Solid Tumors | Phase 1 | Recruiting | CStone Pharmaceuticals | 310 | 2026-07-16 | 2026-08-14 |
| A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors CS2009, Pemetrexed, Carboplatin - Advanced Solid Tumors | Phase 1 / Phase 2 | Recruiting | CStone Pharmaceuticals | 800 | 2025-02-24 | 2026-08-20 |
| Safety and Efficacy of Avapritinib in Chinese Patients With Gastrointestinal Stromal Tumor (GIST) in the Real World Avapritinib, Tyrosine kinase inhibitors other than avapritinib ( imatinib, sunitinib, et al ) - Gastrointestinal Stromal Tumors | Completed | CStone Pharmaceuticals | 61 | 2022-08-29 | 2026-02-11 | |
| A Study of Lorlatinib in Subjects With ROS1-Positive Non-Small Cell Lung Cancer Lorlatinib - Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer | Phase 2 | Active not recruiting | CStone Pharmaceuticals | 70 | 2022-05-27 | 2026-05-19 |
| A Study of CS5001 in Patients With Advanced Solid Tumors and Lymphomas CS5001, Rituximab, Gemcitabine - Advanced Solid Tumor, Advanced Lymphoma | Phase 1 | Suspended | CStone Pharmaceuticals | 480 | 2022-03-28 | 2026-09-01 |
| Safety and Tolerability Evaluation of Low-dose Radiation in Combination With CS1001 in Relapsed SCLC Patients CS1001 - Relapsed Small Cell Lung Cancer | Phase 1 | Completed | CStone Pharmaceuticals | 11 | 2021-01-12 | 2024-03-07 |
| A Study of CS1001 in Combination With Donafenib in Subjects With Advanced Solid Tumors Donafenib, CS1001 - Advanced Solid Tumor | Phase 1 | Unknown | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 30 | 2020-10-15 | 2022-11-29 |
| A Study of CS3005 in Advanced Solid Tumors CS3005 - Advanced Solid Tumor | Phase 1 | Completed | CStone Pharmaceuticals | 9 | 2020-01-10 | 2022-04-27 |
| A Study of CS3002 in Subjects With Advanced Solid Tumors CS3002 - Advanced Solid Tumor | Phase 1 | Terminated | CStone Pharmaceuticals | 10 | 2019-12-30 | 2021-04-15 |
| A Phase I Study of CS1002 in Subjects With Advanced Solid Tumors CS1002 - Advanced Solid Tumor | Phase 1 | Completed | CStone Pharmaceuticals | 6 | 2019-12-27 | 2021-02-21 |
| A Study of CS1001 in Subjects With Esophageal Squamous Cell Carcinoma CS1001+ Fluorouracil+Cisplatin, Placebo+ Fluorouracil+Cisplatin - Unresectable Locally Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma | Phase 3 | Completed | CStone Pharmaceuticals | 540 | 2019-12-19 | 2023-11-24 |
| A Phase Ib/II Study of Fisogatinib(BLU-554) in Subjects With Hepatocellular Carcinoma Phase Ib: Fisogatinib (BLU-554) 400mg in combination with Sugemalimab (CS1001) 1200mg, Phase Ib: Fisogatinib (BLU-554) 600mg in combination with Sugemalimab (CS1001) 1200mg, Phase II: Fisogatinib (BLU-554) 600mg in combination with Sugemalimab (CS1001) 1200mg - Hepatocellular Carcinoma | Phase 1 / Phase 2 | Completed | CStone Pharmaceuticals | 26 | 2019-12-16 | 2023-02-06 |
| A Study of Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular Carcinoma Nofazinlimab (CS1003)+Lenvatinib, Nofazinlimab (CS1003) Placebo+Lenvatinib - Hepatocellular Carcinoma | Phase 3 | Active not recruiting | CStone Pharmaceuticals | 534 | 2019-12-13 | 2026-07-30 |
| A Study of CS1001 in Combination With Regorafenib in Patients With Advanced or Refractory Solid Tumors CS1001, Regorafenib - Advanced Refractory Solid Tumors | Phase 1 / Phase 2 | Completed | CStone Pharmaceuticals | 19 | 2019-12-13 | 2022-05-06 |
| A China Bridging Study of Ivosidenib in r/r AML Subjects With an IDH1 Mutation ivosidenib - Relapsed or Refractory Acute Myeloid Leukemia | Phase 1 | Completed | CStone Pharmaceuticals | 30 | 2019-11-12 | 2023-02-13 |
| A Study of CS3007 in Subjects With Gastrointestinal Stromal Tumor CS3007 (BLU-285) - Gastrointestinal Stromal Tumors | Phase 1 / Phase 2 | Completed | CStone Pharmaceuticals | 65 | 2019-08-15 | 2023-04-27 |
| A Study of CS1001 in Subjects With Gastric Adenocarcinoma or Gastro-Esophageal Junction Adenocarcinoma CS1001 monoclonal antibody, CS1001 placebo, Oxaliplatin - Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma | Phase 3 | Completed | CStone Pharmaceuticals | 479 | 2019-03-28 | 2023-11-29 |
| A Study of CS1001 in Subjects With Stage IV Non-Small Cell Lung Cancer CS1001 monoclonal antibody, CS1001 placebo - Non Small Cell Lung Cancer | Phase 3 | Completed | CStone Pharmaceuticals | 479 | 2018-12-13 | 2026-08-18 |
| A Study of CS1001 in Subjects with Advanced Solid Tumors CS1001 - Advanced Solid Tumors | Phase 1 | Completed | CStone Pharmaceuticals | 24 | 2018-12-04 | 2024-09-19 |
Showing 20 of 29. Sign in to see all of them.
Carcinoma, Hepatocellular (2) · Carcinoma, Non-Small-Cell Lung (2) · Gastrointestinal Stromal Tumors (2) · Recurrence (2) · Esophageal Squamous Cell Carcinoma (1) · Hodgkin Disease (1) · Leukemia, Myeloid, Acute (1) · Lymphoma (1) · Lymphoma, Extranodal NK-T-Cell (1) · Small Cell Lung Carcinoma (1)
Oxaliplatin (4) · CS-1003 (3) · Gemcitabine (3) · Capecitabine (2) · avapritinib (2) · regorafenib (2) · sugemalimab (2) · 130-nm albumin-bound paclitaxel (1) · Carboplatin (1) · Cisplatin (1) · Cyclophosphamide (1) · Docetaxel (1) · Doxorubicin (1) · Etoposide (1) · Fluorouracil (1)
China (21) · Australia (9) · United States (4) · Hong Kong (1) · Italy (1) · Poland (1) · Spain (1) · Taiwan (1)
Yaling Huang (2) · Fei Li, PhD (1) · Lin Shen, MD (1) · Qing Zhou (1) · Qinzhou Qi (1) · Wanmei Wang (1) · Ye Guo, MD (1) · You Lu, MD (1)
PMID 39231855, PMID 30280641, PMID 30316010, PMID 31590988, PMID 31856049, PMID 32417411, PMID 34984540, PMID 35038429, PMID 35038432, PMID 36477870, PMID 36649072, PMID 36996373, PMID 37322367, PMID 37731023, PMID 38302715, PMID 39992668, PMID 40523368